Wall Street Zen Upgrades Sana Biotechnology (NASDAQ:SANA) to “Hold”

Sana Biotechnology (NASDAQ:SANA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities analysts have also issued research reports about the company. Morgan Stanley reissued an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a research note on Friday, March 13th. Rodman & Renshaw initiated coverage on Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Weiss Ratings lowered Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wedbush increased their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Finally, Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Trading Up 5.4%

NASDAQ SANA opened at $3.30 on Friday. The stock has a market cap of $918.36 million, a PE ratio of -3.55 and a beta of 2.17. Sana Biotechnology has a twelve month low of $2.10 and a twelve month high of $6.55. The stock has a fifty day simple moving average of $3.23 and a 200-day simple moving average of $3.84.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Research analysts predict that Sana Biotechnology will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SANA. AQR Capital Management LLC increased its holdings in shares of Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after acquiring an additional 190,483 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after acquiring an additional 90,515 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Sana Biotechnology by 86.8% in the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after acquiring an additional 43,247 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Sana Biotechnology by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after acquiring an additional 21,149 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Sana Biotechnology in the 2nd quarter valued at about $50,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.